If you have lupus nephritis, it’s important to continue to get regular urine tests to monitor how well your kidneys are working — even if you’re being treated for lupus nephritis. According to the ACR ...

Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious than standard therapy alone, according to a new phase 3, placebo ...

Patients were ages 18 to 75 with systemic lupus erythematosus and kidney biopsy-confirmed active class III or IV lupus nephritis, with or without concomitant class V disease.

In addition, 6% shifted to class V, 3% to class II and 6% to a no lupus nephritis classification, defined by lupus podocytopathy and/or focal segmental glomerulosclerosis.

Source Reference: Sammaritano LR, et al "2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis" Arthritis Rheumatol 2025; DOI: 10. ...

The sBLA is supported by data from the randomized, double-blind, placebo-controlled phase 3 REGENCY study (ClinicalTrials.gov Identifier: NCT04221477), which included patients with International ...

WASHINGTON — Early triple therapy may be the most effective strategy for lupus nephritis, according to the new 2024 American College of Rheumatology Guideline for the Screening, Treatment, and ...

Recurrent lupus nephritis post-transplant may go undetected without surveillance biopsies. This study reveals high recurrence ...

For lupus nephritis, you will likely start at a dose of 23.7 milligrams (3 tablets) twice a day with a minimum of 8 hours between each of your doses. Ideally, your doses should be taken 12 hours ...

REGENCY [NCT04221477] is a phase III, randomised, double-blind, placebo-controlled, multicentre study investigating the efficacy and safety of Gazyva/Gazyvaro (obinutuzumab) plus standard therapy ...

Roche announced positive topline results from the phase III REGENCY study of Gazyva/Gazyvaro (obinutuzumab) in people with active lupus nephritis. In the study, a higher proportion of people treated ...